Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Marc Schwartz, MD, University of Colorado, Aurora, CO, discusses institutional outcomes of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who have been treated with induction dasatinib prednisone prior to transplant. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.